 |
PDBsum entry 2fpy
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
|
|
|
|
Oxidoreductase
|
PDB id
|
|
|
|
2fpy
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
References listed in PDB file
|
 |
|
Key reference
|
 |
|
Title
|
 |
Dual binding mode of a novel series of dhodh inhibitors.
|
 |
|
Authors
|
 |
R.Baumgartner,
M.Walloschek,
M.Kralik,
A.Gotschlich,
S.Tasler,
J.Mies,
J.Leban.
|
 |
|
Ref.
|
 |
J Med Chem, 2006,
49,
1239-1247.
[DOI no: ]
|
 |
|
PubMed id
|
 |
|
 |
 |
|
Abstract
|
 |
|
Human dihydroorotate dehydrogenase (DHODH) represents an important target for
the treatment of hyperproliferative and inflammatory diseases. In the cell DHODH
catalyzes the rate-limiting step of the de novo pyrimidine biosynthesis. DHODH
inhibition results in beneficial immunosuppressant and antiproliferative effects
in diseases such as rheumatoid arthritis. Here, we present high-resolution X-ray
structures of human DHODH in complex with a novel class of low molecular weight
compounds that inhibit the enzyme in the nanomolar range. Some compounds showed
an interesting dual binding mode within the same cocrystal strongly depending on
the nature of chemical substitution. Measured in vitro activity data correlated
with the prevailing mode of binding and explained the observed
structure-activity relationship. Additionally, the X-ray data confirmed the
competitive nature of the inhibitors toward the putative ubiquinone binding site
and will guide structure-based design and synthesis of molecules with higher
activity.
|
 |
|
|
|
|
 |